According to Nova one advisor, the global Topical Drug Delivery market size is expected to hit around USD 318.9 billion by 2030 from valued at USD 207.9 billion in 2022 and growing at a CAGR of 8.75% from 2022 to 2030.
The key factors contributing to the industry growth include the increased prevalence of skin disorders coupled with strategic collaborations between key players. The increasing prevalence of skin infections, such as psoriasis, atopic dermatitis, and eczema, coupled with the rising demand for eye and ear therapies is expected to drive the demand for transdermal or dermal medicines during the forecast period. For instance, in October 2021, AbbVie Inc. received FDA approval for Vuity, a pilocarpine HCl ophthalmic solution for treating presbyopia.
In addition, according to the NCBI, the prevalence of psoriasis is nearly 1.98% and 1.8% among European and North American populations. The launch of topical medicines to treat skin diseases is also anticipated to propel the demand for dermal drugs. For instance, in September 2020, Bausch Health, Canada launched a novel antipsoriatic agent, Duobrii lotion for psoriasis patients.Advancements in technology and increased acquisitions and mergers activities among key players, such as Alcon, Inc. and Novartis AG, are anticipated to boost the industry's growth. For instance, in June 2022, Novartis AG acquired Kedalion Therapeutics, thereby acquiring AcuStream technology to facilitate accurate dermal delivery of ophthalmic medicines.
Moreover, in May 2022, Alcon Inc. acquired Eysuvis (loteprednol etabonate suspension) for topical ophthalmic use from Kala Pharmaceuticals, Inc., thereby adding to its existing portfolio of dry eye drugs.A high incidence of burn injuries is expected to render high utilization of topical medicines in treating burn injuries. For instance, according to the WHO, an estimated 11 million burn injuries occur annually worldwide, out of which about 180,000 cases are fatal. Various topical agents are used in treating burn injuries including silver sulfadiazine cream, bismuth-impregnated petroleum gauze, cerium nitrate, mafenide acetate, and nanocrystalline silver among others.
Report Scope of the Topical Drug Delivery Market
Report Coverage |
Details |
Market Size |
USD 318.9 Billion by 2030 |
Growth Rate |
CAGR of 8.75% from 2022 to 2030 |
Largest Market |
North America |
Fastest Growing Market |
Asia Pacific |
Base Year |
2021 |
Forecast Period |
2022 to 2030 |
Segments Covered |
Product, Route of Administration, and Facility of Use And Region |
Companies Mentioned |
Glenmark Pharmaceuticals Ltd. (India), Galderma (Switzerland), Johnson & Johnson Private Limited (US), GlaxoSmithKline Plc. (UK), Bausch Health Companies Inc. (Canada), Hisamitsu Pharmaceuticals Inc. (Japan), Cipla (India), Bayer AG (Germany), Viatris Inc. (Mylan N.V.) (US), 3M (US), Merck & Co.Inc.. (Germany), Crescita Therpeautics Inc. (Canada), Novartis International AG (Switzerland), Boehringer Ingelheim International GmBH (Germany), Pfizer Inc. (US), Teva Pharmaceuticals Industries Ltd. (Israel), Bristol Myers Squibb (US), Lead Chemical Co., Ltd. (Japan), Purdue Pharma L.P. (US), Lavipharm (Greece), AbbVie Inc. (US), CMP Pharma, Inc. (Germany), Encore Dermatology, Inc. (US), Prosolus Inc. (US), and Rusan Pharma Ltd. (India). |
Topical Drug Delivery Market Dynamics
Driver: High Incidence of burn injuries
The treatment of burn injuries is one of the major application areas of topical drugs. Topical antimicrobial agents such as Fenistil (GSK), Sulfamylon cream (Mylan), Bactroban (GSK), and Silvadene (Pfizer) are considered the first line of treatment for burn injuries in patients.
According to the Lancet Public Health, in 2021, burns were one of the major causes of disability, with more than 8 million disability-adjusted life-years (DALYs). The high incidence of burn injuries in major regional segments across the globe has resulted in sustained demand for topical drugs for effective burn treatment and management. Many topical antimicrobial agents are used to cure burns. An antimicrobial agent such as silver sulfadiazine cream is used to treat wound infections in second and third-degree burns patients. However, patients with severe burns or burns over a large area are treated in a hospital. There are many other antibiotic ointments for burns, such as over-the-counter options for an uncomplicated burn.
Restraint: Continuous irritation on skin and allergies caused by topical drugs
Many topical formulations are available over the counter and include antibacterial & antifungal preparations, anti-inflammatory & pain-relief preparations, and cleansing & moisturizing agents. Topical corticosteroids are used in many inflammatory rashes. However, in some cases, topical corticosteroid sensitivity produces allergic reactions. Usually, this is seen as a failure to cure dermatitis or to worsen existing dermatitis treated with corticosteroids. Very rarely, corticosteroid allergy may appear as an eczematous rash in a completely different area of the body from the original dermatitis. Some topical antibiotics may also cause contact allergies, such as bacitracin, which is used to prevent minor skin injuries such as cuts, scrapes, and burns. Benzocaine and salicylate are some of the active ingredients in topical formulations which causes allergies. These allergies caused by such drugs can be diagnosed by a patch test that can detect contact allergens. Allergy to topical medications is more common in older patients, but some patients with pre-existing skin conditions are at a higher risk of developing allergic reactions to topical medications. These allergies caused by the topical drugs are one of the limitations of the usage of such medicines. In most cases, patients adopt another type of drug delivery system or go for other forms of medicine.
Opportunity: Rising demand for self-administration and home care
Self-administration of drugs within home care settings is expected to provide significant growth opportunities for players operating in the topical drug delivery market. This is mainly due to the rising geriatric population and closing regular OPDs for a few months during COVID-19. Elderly individuals form a large consumer base for topical drugs in-home care. This factor also increases the need for inhalation, topical, and transdermal drug products designed to cater to the needs of caregivers and patients. Transdermal drug delivery enhances the ease of administration of drugs as it uses a transdermal patch that can be easily self-administered. It provides suitable and painless self-administration for patients. This approach helps reduce healthcare costs by reducing the duration of hospital stays. Also, in the case of transdermal patches, caregivers can easily determine if a patch is placed securely. This acts as one of the main opportunities to increase the demand for transdermal patches, boosting the growth of topical drug deliveries.
Challenge: Topical formulation for drugs with limited plasma concentration
Topical drug delivery refers to the application of medication to the surface of the skin or within the layers of skin or mucous membrane. Skin acts as a barrier and prevents the penetration of many APIs, even though it is an ideal site to achieve both local and systemic effects via the delivery of drug substances. However, drugs that have a larger particle size are not easily absorbed through the skin. To facilitate skin absorption, the molecular weight of a compound should be under 500 Dalton when developing drug substances for use in topical dermatological therapies. These high molecular weight drugs are poorly lipid-soluble and cannot achieve the desired therapeutic effect and action. Percutaneous absorption decreases with high molecular weight. This decreased therapeutic effect of topical medicines limits the adoption of topical drug delivery.
The semi-solid formulation segment accounted for the largest share of the topical drug delivery market, by product in 2021
Based on products, the topical drug delivery the market is segmented into semi-solid formulations, liquid formulations, solid formulations, and transdermal products. In 2021, the semi-solid formulations segment accounted for the largest share in the market. The large share of this segment is attributed to suitability to APIs with low density, more stable in atmospheric conditions than liquid and solid forms, and rise in personalized medicine as they have a unique composition and increased absorptive properties. These dosage forms are non-dehydrating and make no modifications to skin functioning.
The dermal drug delivery segment accounted for the largest share of the topical drug delivery market, by route of administration in 2021
Based on the route of administration, the market is segmented into dermal, ophthalmic, rectal, vaginal, and nasal drug delivery. The large share of the dermal drug delivery market segment can largely be attributed to pain free self-administration for patients, advantageous for drugs with shorter half-lives or narrow therapeutic indices, and elimination of frequent administration of drugs and plasma level peaks and valleys associated with oral dosing and injections to maintain a constant drug concentration.
The home care settings segment accounted for the largest share of the topical drug delivery market, by facility of use in 2021
Based on the facility of use, the market is segmented into home care settings, hospitals & clinics, burn centers, and other facilities. The large share of home care settings segment can be attributed to advantages for long-term therapy, better convenience in comparison with inpatient care, and improvement in medical adherence and treatment outcomes. The increasing geriatric population across the globe and the growing need for self- administration of drugs are some other important factors influencing the growth of the home care settings segment.
North America accounted for the largest share of the topical drug delivery market in 2021
In 2021, North America accounted for the largest share the topical drug delivery market, followed by Europe, Asia Pacific, Latin America, and the Middle East & Africa. The large share of North America can be attributed to the rising prevalence of target health conditions, the increasing preference for pain-free drug delivery solutions, the growing prevalence of skin diseases, an increasing number of smokers around the world, rising advancements in transdermal patches, and the high demand for drugs that can be self-administered.
Recent Developments
Some of the prominent players in the Topical Drug Delivery Market include:
Glenmark Pharmaceuticals Ltd. (India), Galderma (Switzerland), Johnson & Johnson Private Limited (US), GlaxoSmithKline Plc. (UK), Bausch Health Companies Inc. (Canada), Hisamitsu Pharmaceuticals Inc. (Japan), Cipla (India), Bayer AG (Germany), Viatris Inc. (Mylan N.V.) (US), 3M (US), Merck & Co.Inc.. (Germany), Crescita Therpeautics Inc. (Canada), Novartis International AG (Switzerland), Boehringer Ingelheim International GmBH (Germany), Pfizer Inc. (US), Teva Pharmaceuticals Industries Ltd. (Israel), Bristol Myers Squibb (US), Lead Chemical Co., Ltd. (Japan), Purdue Pharma L.P. (US), Lavipharm (Greece), AbbVie Inc. (US), CMP Pharma, Inc. (Germany), Encore Dermatology, Inc. (US), Prosolus Inc. (US), and Rusan Pharma Ltd. (India).
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Topical Drug Delivery market
Global Topical Drug Delivery Market, by Product
Global Topical Drug Delivery Market, by Route of Administration
Global Topical Drug Delivery Market, by Facility of Use
By Regional Outlook
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Key Benefits for Stakeholders
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 36)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION AND SCOPE
1.2.1 INCLUSIONS & EXCLUSIONS
1.2.2 MARKETS COVERED
FIGURE 1 TOPICAL DRUG DELIVERY MARKET SEGMENTATION
1.2.3 YEARS CONSIDERED
1.3 CURRENCY
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 40)
2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 3 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE PARTICIPANTS
2.2 MARKET SIZE ESTIMATION
FIGURE 6 MARKET SIZE APPROACH: REVENUE SHARE ANALYSIS
FIGURE 7 TOPICAL DRUG DELIVERY MARKET - REVENUE SHARE ANALYSIS ILLUSTRATION: JOHNSON & JOHNSON
FIGURE 8 PHARMACEUTICAL SALES APPROACH
FIGURE 9 TOP-DOWN APPROACH
FIGURE 10 CAGR PROJECTIONS
FIGURE 11 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN TOPICAL DRUG DELIVERY MARKET (2022–2030): IMPACT ON MARKET GROWTH & CAGR
2.3 MARKET BREAKDOWN & DATA TRIANGULATION
FIGURE 12 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ANALYSIS
2.5 STUDY ASSUMPTIONS
2.6 LIMITATIONS
2.6.1 METHODOLOGY-RELATED LIMITATIONS
2.6.2 SCOPE-RELATED LIMITATIONS
2.7 RISK ASSESSMENT
TABLE 2 RISK ASSESSMENT: TOPICAL DRUG DELIVERY MARKET
3 EXECUTIVE SUMMARY (Page No. - 54)
FIGURE 13 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2022 VS. 2030
FIGURE 14 TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022 VS. 2030
FIGURE 15 TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2022 VS. 2030
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF TOPICAL DRUG DELIVERY MARKET
4 PREMIUM INSIGHTS (Page No. - 58)
4.1 TOPICAL DRUG DELIVERY MARKET OVERVIEW
FIGURE 17 HIGH PREVALENCE OF SKIN DISEASES AND HIGH INCIDENCE OF BURN INJURIES TO DRIVE MARKET GROWTH
4.2 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT AND COUNTRY (2021)
FIGURE 18 SEMI-SOLID FORMULATIONS TO DOMINATE LATIN AMERICA MARKET IN 2021
4.3 TOPICAL DRUG DELIVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 19 INDIA TO REGISTER HIGHEST GROWTH IN MARKET DURING FORECAST PERIOD
4.4 TOPICAL DRUG DELIVERY MARKET, BY REGION (2022–2030)
FIGURE 20 NORTH AMERICA TO DOMINATE MARKET IN 2030
4.5 TOPICAL DRUG DELIVERY MARKET: DEVELOPED VS. DEVELOPING MARKETS
FIGURE 21 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 62)
5.1 INTRODUCTION
5.2 PRICING ANALYSIS
TABLE 3 TOPICAL DRUG DELIVERY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 High prevalence of skin diseases
5.2.1.2 Increase in self-medication as a popular practice in dermatology
5.2.1.3 High prevalence of topical prescription therapy for dry eye diseases
5.2.1.4 Switching from conventional needle injections to transdermal patches
5.2.1.5 High incidence of burn injuries
5.2.1.6 Growing prevalence of diabetes
5.2.2 RESTRAINTS
5.2.2.1 Continuous irritation of skin and allergies caused by topical drugs
5.2.2.2 Preference for alternative modes of drug delivery
5.2.3 OPPORTUNITIES
5.2.3.1 Rising demand for self-administration and home care
5.2.3.2 Delivery of biologics through transdermal route
5.2.3.3 Topical vehicles used in cosmetic industry
5.2.4 CHALLENGES
5.2.4.1 Topical formulations for drugs with limited plasma concentration
5.2.4.2 Increasing number of drug failures and product recalls
5.3 PORTER’S FIVE FORCES ANALYSIS
5.3.1 NEW ADVANCEMENT IN TRANSDERMAL DRUG DELIVERY SYSTEM
5.3.2 ADOPTION OF TELEDERMATOLOGY
5.4 PATENT ANALYSIS
TABLE 4 TOPICAL DRUG DELIVERY MARKET: DETAILED LIST OF CONFERENCES & EVENTS
5.5 MARKET DYNAMICS
5.6 INDUSTRY TRENDS
TABLE 5 REGULATORY SCENARIO, BY COUNTRY
5.7 KEY CONFERENCES & EVENTS IN 2022-2023
FIGURE 22 TOPICAL DRUG DELIVERY MARKET: VALUE CHAIN ANALYSIS
5.8 IMPACT OF COVID-19
FIGURE 23 PHARMACEUTICAL DRUG DELIVERY MARKET ECOSYSTEM
5.9 REGULATORY ANALYSIS
5.10 VALUE CHAIN ANALYSIS
TABLE 6 REGIONAL PRICING ANALYSIS OF TOPICAL DRUGS, 2021 (USD)
5.11 ECOSYSTEM MAPPING
TABLE 7 TOPICAL DRUG DELIVERY MARKET: PORTER’S FIVE FORCES ANALYSIS
5.11.1 THREAT OF NEW ENTRANTS
5.11.2 THREAT OF SUBSTITUTES
5.11.3 BARGAINING POWER OF SUPPLIERS
5.11.4 BARGAINING POWER OF BUYERS
5.11.5 INTENSITY OF COMPETITIVE RIVALRY
5.12 TECHNOLOGY ANALYSIS
5.12.1 PATENT PUBLICATION TRENDS FOR TOPICAL DRUG DELIVERY
FIGURE 24 PATENT PUBLICATION TRENDS (JANUARY 2011– APRIL 2022)
5.12.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
FIGURE 25 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR TOPICAL DRUG DELIVERY PATENTS (JANUARY 2011–APRIL 2022)
FIGURE 26 TOP APPLICANT COUNTRIES/REGIONS FOR TOPICAL DRUG DELIVERY (JANUARY 2011–APRIL 2022)
TABLE 8 LIST OF PATENTS/PATENT APPLICATIONS IN TOPICAL DRUG DELIVERY MARKET, 2021–2022
6 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT (Page No. - 84)
6.1 INTRODUCTION
TABLE 9 TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2022–2030
6.2 SEMI-SOLID FORMULATIONS
TABLE 10 KEY TOPICAL DRUG DELIVERY SEMI-SOLID FORMULATIONS AVAILABLE
TABLE 11 TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2022–2030
TABLE 12 TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY COUNTRY, 2022–2030
6.2.1 OINTMENTS
6.2.1.1 Ointments to be widely used in analgesic indications
TABLE 13 TOPICAL DRUG DELIVERY MARKET FOR OINTMENTS, BY COUNTRY, 2022–2030
6.2.2 CREAMS
6.2.2.1 Creams to be most widely used formulation due to better absorption
TABLE 14 TOPICAL DRUG DELIVERY MARKET FOR CREAMS, BY COUNTRY, 2022–2030
6.2.3 LOTIONS
6.2.3.1 Easy administration of lotions to drive demand
TABLE 15 TOPICAL DRUG DELIVERY MARKET FOR LOTIONS, BY COUNTRY, 2022–2030
6.2.4 GELS
6.2.4.1 Faster drug release and greater patient acceptability to drive gels market
TABLE 16 TOPICAL DRUG DELIVERY MARKET FOR GELS, BY COUNTRY, 2022–2030
6.2.5 PASTES
6.2.5.1 Topical pastes to treat and prevent skin irritation
TABLE 17 TOPICAL DRUG DELIVERY MARKET FOR PASTES, BY COUNTRY, 2022–2030
6.3 LIQUID FORMULATIONS
TABLE 18 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2022–2030
TABLE 19 TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY COUNTRY, 2022–2030
TABLE 20 KEY LIQUID FORMULATIONS AVAILABLE
6.3.1 SUSPENSIONS
6.3.1.1 Higher rate of bioavailability and controlled onset of action to support market growth
TABLE 21 TOPICAL DRUG DELIVERY MARKET FOR SUSPENSIONS, BY COUNTRY, 2022–2030
6.3.2 SOLUTIONS
6.3.2.1 Topical solutions with soluble chemicals to dissolve in various solvents
TABLE 22 TOPICAL DRUG DELIVERY MARKET FOR SOLUTIONS, BY COUNTRY, 2022–2030
6.4 SOLID FORMULATIONS
TABLE 23 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2022–2030
TABLE 24 TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY COUNTRY, 2022–2030
TABLE 25 KEY SOLID FORMULATIONS AVAILABLE
6.4.1 POWDERS
6.4.1.1 Inexpensive manufacturing and effectiveness against antifungal infections to propel powders market
TABLE 26 TOPICAL DRUG DELIVERY MARKET FOR POWDERS, BY COUNTRY, 2022–2030
6.4.2 SUPPOSITORIES
6.4.2.1 Suppositories require suitable base to ensure drug compatibility and stability
TABLE 27 TOPICAL DRUG DELIVERY MARKET FOR SUPPOSITORIES , BY COUNTRY, 2022–2030
6.5 TRANSDERMAL PRODUCTS
TABLE 28 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2022–2030
TABLE 29 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY COUNTRY, 2022–2030
TABLE 30 KEY TRANSDERMAL PRODUCTS AVAILABLE
6.5.1 TRANSDERMAL PATCHES
6.5.1.1 Transdermal patches to offer increased drug permeability across skin
TABLE 31 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PATCHES, BY COUNTRY, 2022–2030
6.5.2 TRANSDERMAL SEMI-SOLIDS
6.5.2.1 Transdermal semi-solids to offer fast drying on application site
TABLE 32 TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL SEMI-SOLIDS, BY COUNTRY, 2022–2030
7 TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION (Page No. - 107)
7.1 INTRODUCTION
TABLE 33 TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030
7.2 DERMAL DRUG DELIVERY
7.2.1 NANO-SIZED DRUG CARRIER SYSTEMS TO BE STUDIED TO OVERCOME DRUG PENETRATION LIMITATION
TABLE 34 DERMAL DRUG DELIVERY MARKET, BY COUNTRY, 2022–2030
7.3 OPHTHALMIC DRUG DELIVERY
7.3.1 MICROEMULSION-BASED FORMULATIONS LEAD TO BETTER OCULAR DRUG ADSORPTION
TABLE 35 OPHTHALMIC DRUG DELIVERY MARKET, BY COUNTRY, 2022–2030
7.4 VAGINAL DRUG DELIVERY
7.4.1 RICH AND COMPLEX NETWORK OF CAPILLARIES OF UPPER VAGINA TO CREATE SYSTEMIC DRUG DELIVERY SYSTEM
TABLE 36 VAGINAL DRUG DELIVERY MARKET, BY COUNTRY, 2022–2030
7.5 RECTAL DRUG DELIVERY
7.5.1 RECTAL ADMINISTRATION TO ENABLE BOTH LOCAL AND SYSTEMIC THERAPY OF DRUGS
TABLE 37 RECTAL DRUG DELIVERY MARKET, BY COUNTRY, 2022–2030
7.6 NASAL DRUG DELIVERY
7.6.1 NASAL DELIVERY ROUTE OFFERS QUICK ONSET OF DRUG ACTION AND CONVENIENCE AS COMPARED TO PARENTERAL ROUTE
TABLE 38 NASAL DRUG DELIVERY MARKET, BY COUNTRY, 2022–2030
8 TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE (Page No. - 118)
8.1 INTRODUCTION
TABLE 39 TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2022–2030
8.2 HOMECARE SETTINGS
8.2.1 HOMECARE TO DOMINATE MARKET DURING FORECAST PERIOD
TABLE 40 TOPICAL DRUG DELIVERY MARKET FOR HOMECARE SETTINGS, BY COUNTRY, 2022–2030
8.3 HOSPITALS & CLINICS
8.3.1 TOPICAL ANAESTHETICS TO BE ADOPTED FOR VARIOUS MEDICAL AND SURGICAL SUB-SPECIALTIES
TABLE 41 TOPICAL DRUG DELIVERY MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2030
8.4 BURN CENTERS
8.4.1 TOPICAL ANTIMICROBIAL FORMULATIONS FOR BURN-RELATED INJURIES TO DRIVE MARKET GROWTH
TABLE 42 TOPICAL DRUG DELIVERY MARKET FOR BURN CENTERS, BY COUNTRY, 2022–2030
8.5 OTHER FACILITIES
TABLE 43 TOPICAL DRUG DELIVERY MARKET FOR OTHER FACILITIES, BY COUNTRY, 2022–2030
9 TOPICAL DRUG DELIVERY MARKET, BY REGION (Page No. - 126)
9.1 INTRODUCTION
FIGURE 27 TOPICAL DRUG DELIVERY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
TABLE 44 TOPICAL DRUG DELIVERY MARKET, BY REGION, 2022–2030
9.2 NORTH AMERICA
FIGURE 28 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET SNAPSHOT
TABLE 45 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2022–2030
TABLE 46 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2022–2030
TABLE 47 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2022–2030
TABLE 48 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2022–2030
TABLE 49 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2022–2030
TABLE 50 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2022–2030
TABLE 51 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030
TABLE 52 NORTH AMERICA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2022–2030
9.2.1 US
9.2.1.1 Rising prevalence of skin diseases alongside approval and launch of innovative topical formulations to propel market growth
TABLE 53 US: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2022–2030
TABLE 54 US: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2022–2030
TABLE 55 US: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2022–2030
TABLE 56 US: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2022–2030
TABLE 57 US: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2022–2030
TABLE 58 US: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030
TABLE 59 US: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2022–2030
9.2.2 CANADA
9.2.2.1 Rising prevalence of hypertension and funding for topical drugs research to drive market growth
TABLE 60 CANADA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2022–2030
TABLE 61 CANADA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2022–2030
TABLE 62 CANADA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2022–2030
TABLE 63 CANADA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2022–2030
TABLE 64 CANADA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2022–2030
TABLE 65 CANADA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030
TABLE 66 CANADA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2022–2030
9.3 EUROPE
TABLE 67 RECENT DEVELOPMENTS IN EUROPEAN TOPICAL DRUG DELIVERY MARKET, 2019–2022
TABLE 68 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2022–2030
TABLE 69 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2022–2030
TABLE 70 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2022–2030
TABLE 71 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2022–2030
TABLE 72 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2022–2030
TABLE 73 EUROPE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2022–2030
TABLE 74 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030
TABLE 75 EUROPE: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2022–2030
9.3.1 GERMANY
9.3.1.1 Growing focus of pharmaceutical companies on topical products development and increasing target diseases to drive market growth
TABLE 76 DEVELOPMENTS AND PRODUCT LAUNCHES IN TOPICAL DRUG DELIVERY IN GERMANY, 2019–2022
TABLE 77 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2022–2030
TABLE 78 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2022–2030
TABLE 79 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2022–2030
TABLE 80 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2022–2030
TABLE 81 GERMANY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2022–2030
TABLE 82 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030
TABLE 83 GERMANY: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2022–2030
9.3.2 UK
9.3.2.1 Increasing developments by top players and demand for pain-free treatment to drive market growth
TABLE 84 UK: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2022–2030
TABLE 85 UK: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2022–2030
TABLE 86 UK: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2022–2030
TABLE 87 UK: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2022–2030
TABLE 88 UK: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)
TABLE 89 UK: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030
TABLE 90 UK: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2022–2030
9.3.3 FRANCE
9.3.3.1 Rising prevalence of diabetes and increasing geriatric population to support market growth
TABLE 91 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2022–2030
TABLE 92 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2022–2030
TABLE 93 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2022–2030
TABLE 94 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2022–2030
TABLE 95 FRANCE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2022–2030
TABLE 96 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030
TABLE 97 FRANCE: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2022–2030
9.3.4 ITALY
9.3.4.1 Rising number of smokers to propel transdermal patches demand
TABLE 98 ITALY: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2022–2030
TABLE 99 ITALY: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2022–2030
TABLE 100 ITALY: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2022–2030
TABLE 101 ITALY: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2022–2030
TABLE 102 ITALY: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2022–2030
TABLE 103 ITALY: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030
TABLE 104 ITALY: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2022–2030
9.3.5 SPAIN
9.3.5.1 Growing diabetic patients to drive market growth
TABLE 105 SPAIN: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2022–2030
TABLE 106 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2022–2030
TABLE 107 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2022–2030
TABLE 108 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2022–2030
TABLE 109 SPAIN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2022–2030
TABLE 110 SPAIN: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030
TABLE 111 SPAIN: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2022–2030
9.3.6 SWITZERLAND
9.3.6.1 Rising geriatric population and emerging players focusing on topical drugs development to drive market growth
TABLE 112 SWITZERLAND: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2022–2030
TABLE 113 SWITZERLAND: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2022–2030
TABLE 114 SWITZERLAND: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2022–2030
TABLE 115 SWITZERLAND: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2022–2030
TABLE 116 SWITZERLAND: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2022–2030
TABLE 117 SWITZERLAND: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030
TABLE 118 SWITZERLAND: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2022–2030
9.3.7 REST OF EUROPE
TABLE 119 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2022–2030
TABLE 120 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2022–2030
TABLE 121 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2022–2030
TABLE 122 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2022–2030
TABLE 123 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2022–2030
TABLE 124 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030
TABLE 125 REST OF EUROPE: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2022–2030
9.4 ASIA PACIFIC
FIGURE 29 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET SNAPSHOT
TABLE 126 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2022–2030
TABLE 127 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2022–2030
TABLE 128 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, BY TYPE, 2022–2030
TABLE 129 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2022–2030
TABLE 130 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2022–2030
TABLE 131 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2022–2030
TABLE 132 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030
TABLE 133 ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2022–2030
9.4.1 CHINA
9.4.1.1 Prevalence of diabetes and increase in pharmaceutical R&D investments to drive market growth
TABLE 134 CHINA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2022–2030
TABLE 135 CHINA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, BY TYPE, 2022–2030
TABLE 136 CHINA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2022–2030
TABLE 137 CHINA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2022–2030
TABLE 138 CHINA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2022–2030
TABLE 139 CHINA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030
TABLE 140 CHINA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2022–2030
9.4.2 JAPAN
9.4.2.1 Increasing number of product approvals and growing focus of local players on topical formulations R&D to support market growth
TABLE 141 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2022–2030
TABLE 142 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, BY TYPE, 2022–2030
TABLE 143 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2022–2030
TABLE 144 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2022–2030
TABLE 145 JAPAN: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2022–2030
TABLE 146 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030
TABLE 147 JAPAN: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2022–2030
9.4.3 INDIA
9.4.3.1 Rising awareness among healthcare providers and patients alongside increasing focus on noninvasive methods of drug delivery to drive market growth
TABLE 148 INDIA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2022–2030
TABLE 149 INDIA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, BY TYPE, 2022–2030
TABLE 150 INDIA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2022–2030
TABLE 151 INDIA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2022–2030
TABLE 152 INDIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)
TABLE 153 INDIA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030
TABLE 154 INDIA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2022–2030
9.4.4 AUSTRALIA
9.4.4.1 Increasing number of smokers to drive market growth
TABLE 155 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2022–2030
TABLE 156 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2022–2030
TABLE 157 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2022–2030
TABLE 158 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2022–2030
TABLE 159 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2022–2030
TABLE 160 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030
TABLE 161 AUSTRALIA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2022–2030
9.4.5 REST OF ASIA PACIFIC
TABLE 162 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2022–2030
TABLE 163 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2022–2030
TABLE 164 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2022–2030
TABLE 165 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2022–2030
TABLE 166 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2022–2030
TABLE 167 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030
TABLE 168 REST OF ASIA PACIFIC: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2022–2030
9.5 LATIN AMERICA
TABLE 169 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2022–2030
TABLE 170 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2022–2030
TABLE 171 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, BY TYPE, 2022–2030
TABLE 172 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2022–2030
TABLE 173 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2022–2030
TABLE 174 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2022–2030
TABLE 175 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030
TABLE 176 LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2022–2030
9.5.1 BRAZIL
9.5.1.1 High prevalence of diabetes to propel market growth
TABLE 177 BRAZIL: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2022–2030
TABLE 178 BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, BY TYPE, 2022–2030
TABLE 179 BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2022–2030
TABLE 180 BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2022–2030
TABLE 181 BRAZIL: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2022–2030
TABLE 182 BRAZIL: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030
TABLE 183 BRAZIL: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2022–2030
9.5.2 MEXICO
9.5.2.1 Increasing prevalence of glaucoma to drive market growth
TABLE 184 MEXICO: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2022–2030
TABLE 185 MEXICO: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, BY TYPE, 2022–2030
TABLE 186 MEXICO: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2022–2030
TABLE 187 MEXICO: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2022–2030
TABLE 188 MEXICO: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2022–2030
TABLE 189 MEXICO: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030
TABLE 190 MEXICO: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2022–2030
9.5.3 REST OF LATIN AMERICA
TABLE 191 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2022–2030
TABLE 192 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, 2022–2030
TABLE 193 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2022–2030
TABLE 194 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2022–2030
TABLE 195 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2022–2030
TABLE 196 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030
TABLE 197 REST OF LATIN AMERICA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2022–2030
9.6 MIDDLE EAST & AFRICA
9.6.1 GROWING PREVALENCE OF BURN INJURIES AND INCREASING EXPENDITURE ON HEALTHCARE TO DRIVE MARKET GROWTH
TABLE 198 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY PRODUCT, 2022–2030
TABLE 199 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR SEMI-SOLID FORMULATIONS, BY TYPE, BY TYPE, 2022–2030
TABLE 200 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR LIQUID FORMULATIONS, BY TYPE, 2022–2030
TABLE 201 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR SOLID FORMULATIONS, BY TYPE, 2022–2030
TABLE 202 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET FOR TRANSDERMAL PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)
TABLE 203 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2022–2030
TABLE 204 MIDDLE EAST & AFRICA: TOPICAL DRUG DELIVERY MARKET, BY FACILITY OF USE, 2022–2030
10 COMPETITIVE LANDSCAPE (Page No. - 204)
10.1 OVERVIEW
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS
10.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 30 REVENUE ANALYSIS OF TOP PLAYERS IN TOPICAL DRUG DELIVERY MARKET
10.4 MARKET SHARE ANALYSIS
FIGURE 31 TOPICAL DRUG DELIVERY MARKET SHARE, BY KEY PLAYER, 2021
TABLE 205 TOPICAL DRUG DELIVERY MARKET: DEGREE OF COMPETITION
10.5 COMPETITIVE LEADERSHIP MAPPING
10.5.1 STARS
10.5.2 EMERGING LEADERS
10.5.3 PERVASIVE PLAYERS
10.5.4 PARTICIPANTS
FIGURE 32 TOPICAL DRUG DELIVERY MARKET: COMPETITIVE LEADERSHIP MAPPING (2021)
10.6 COMPETITIVE LEADERSHIP MAPPING FOR OTHER PLAYERS
10.6.1 PROGRESSIVE COMPANIES
10.6.2 DYNAMIC COMPANIES
10.6.3 STARTING BLOCKS
10.6.4 RESPONSIVE COMPANIES
FIGURE 33 TOPICAL DRUG DELIVERY MARKET: COMPETITIVE LEADERSHIP MAPPING FOR OTHER PLAYERS (2021)
10.7 COMPANY FOOTPRINT
TABLE 206 COMPANY FOOTPRINT: TOPICAL DRUG DELIVERY MARKET
10.7.1 PRODUCT FOOTPRINT OF MAJOR PLAYERS
TABLE 207 PRODUCT FOOTPRINT: TOPICAL DRUG DELIVERY MARKET (2021)
10.7.2 ROUTE OF ADMINISTRATION FOOTPRINT OF TOPICAL DRUG DELIVERY MARKET
TABLE 208 ROUTE OF ADMINISTRATION FOOTPRINT: TOPICAL DRUG DELIVERY MARKET (2021)
10.7.3 FACILITY OF USE IN TOPICAL DRUG DELIVERY MARKET
TABLE 209 FACILITY OF USE FOOTPRINT: TOPICAL DRUG DELIVERY MARKET (2021)
10.7.4 GEOGRAPHIC FOOTPRINT OF MAJOR PLAYERS IN TOPICAL DRUG DELIVERY MARKET
TABLE 210 GEOGRAPHIC FOOTPRINT: TOPICAL DRUG DELIVERY MARKET (2021)
10.8 COMPETITIVE SCENARIO
10.8.1 PRODUCT LAUNCHES
TABLE 211 PRODUCT LAUNCHES, JANUARY 2019–APRIL 2022
10.8.2 DEALS
TABLE 212 DEALS, JANUARY 2019–APRIL 2022
10.8.3 OTHER DEVELOPMENTS
TABLE 213 OTHER DEVELOPMENTS, JANUARY 2019–APRIL 2022
11 COMPANY PROFILES (Page No. - 222)
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
11.1 KEY PLAYERS
11.2 OTHER PLAYERS
11.1.1 GLENMARK PHARMACEUTICALS LTD.
TABLE 214 GLENMARK PHARMACEUTICALS LTD.: BUSINESS OVERVIEW
FIGURE 34 GLENMARK PHARMACEUTICALS LTD.: COMPANY SNAPSHOT (2021)
11.1.2 GALDERMA
TABLE 215 GALDERMA: BUSINESS OVERVIEW
11.1.3 JOHNSON & JOHNSON PRIVATE LIMITED
TABLE 216 JOHNSON & JOHNSON PRIVATE LIMITED: BUSINESS OVERVIEW
FIGURE 35 JOHNSON & JOHNSON PRIVATE LIMITED: COMPANY SNAPSHOT (2021)
11.1.4 GLAXOSMITHKLINE PLC.
TABLE 217 GLAXOSMITHKLINE PLC: BUSINESS OVERVIEW
FIGURE 36 GLAXOSMITHKLINE, PLC.: COMPANY SNAPSHOT (2021)
11.1.5 BAUSCH HEALTH COMPANIES INC.
TABLE 218 BAUSCH HEALTH COMPANIES INC.: BUSINESS OVERVIEW
FIGURE 37 BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT (2021)
11.1.6 HISAMITSU PHARMACEUTICAL CO., INC.
TABLE 219 HISAMITSU PHARMACEUTICAL CO., INC.: BUSINESS OVERVIEW
FIGURE 38 HISAMITSU PHARMACEUTICAL CO., INC.: COMPANY SNAPSHOT (2021)
11.1.7 CIPLA
TABLE 220 CIPLA: BUSINESS OVERVIEW
FIGURE 39 CIPLA: COMPANY SNAPSHOT (2021)
11.1.8 BAYER AG
TABLE 221 BAYER AG: BUSINESS OVERVIEW
FIGURE 40 BAYER AG: COMPANY SNAPSHOT (2021)
11.1.9 VIATRIS INC. (MYLAN N.V.)
TABLE 222 VIATRIS INC.: BUSINESS OVERVIEW
FIGURE 41 VIATRIS INC.: COMPANY SNAPSHOT (2021)
11.1.10 3M
TABLE 223 3M: BUSINESS OVERVIEW
FIGURE 42 3M: COMPANY SNAPSHOT (2021)
11.1.11 MERCK & CO., INC.
TABLE 224 MERCK & CO., INC.: BUSINESS OVERVIEW
FIGURE 43 MERCK & CO., INC.: COMPANY SNAPSHOT (2021)
11.1.12 CRESCITA THERAPEUTICS INC.
TABLE 225 CRESCITA THERAPEUTICS INC.: BUSINESS OVERVIEW
FIGURE 44 CRESCITA THERAPEUTICS INC.: COMPANY SNAPSHOT (2021)
11.1.13 NOVARTIS INTERNATIONAL AG
TABLE 226 NOVARTIS INTERNATIONAL: BUSINESS OVERVIEW
FIGURE 45 NOVARTIS INTERNATIONAL AG: COMPANY SNAPSHOT (2021)
11.1.14 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
TABLE 227 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: BUSINESS OVERVIEW
FIGURE 46 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2021)
11.1.15 PFIZER INC.
TABLE 228 PFIZER INC.: BUSINESS OVERVIEW
FIGURE 47 PFIZER INC.: COMPANY SNAPSHOT (2021)
11.1.16 TEVA PHARMACEUTICAL INDUSTRIES LTD.
TABLE 229 TEVA PHARMACEUTICAL INDUSTRIES LTD.: BUSINESS OVERVIEW
FIGURE 48 TEVA PHARMACEUTICALS: COMPANY SNAPSHOT (2021)
11.1.17 BRISTOL MYERS SQUIBB
TABLE 230 BRISTOL MYERS SQUIBB: BUSINESS OVERVIEW
FIGURE 49 BRISTOL MYERS SQUIBB: COMPANY SNAPSHOT (2021)
11.1.18 LEAD CHEMICAL CO., LTD.
TABLE 231 LEAD CHEMICAL CO., LTD.: BUSINESS OVERVIEW
11.1.19 PURDUE PHARMA L.P.
TABLE 232 PURDUE PHARMA L.P.: BUSINESS OVERVIEW
11.1.20 LAVIPHARM
TABLE 233 LAVIPHARM: BUSINESS OVERVIEW
11.1.21 ABBVIE INC.
TABLE 234 ABBVIE INC.: BUSINESS OVERVIEW
FIGURE 50 ABBVIE INC.: COMPANY SNAPSHOT (2021)
12.1 INSIGHTS FROM INDUSTRY EXPERTS
11.2.1 CMP PHARMA, INC.
11.2.2 ENCORE DERMATOLOGY, INC.
11.2.3 PROSOLUS INC.
11.2.4 RUSAN PHARMA LTD.
12.2 DISCUSSION GUIDE
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
12 APPENDIX (Page No. - 298)
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.4 AVAILABLE CUSTOMIZATIONS
12.5 RELATED REPORTS
12.6 AUTHOR DETAILS